{
    "title": "104_s2178",
    "content": "The Act titled \"Better Pharmaceuticals for Children Act\" introduces pediatric studies marketing exclusivity under a new section 505A of the Federal Food, Drug, and Cosmetic Act. The Act \"Better Pharmaceuticals for Children Act\" introduces market exclusivity for pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act, extending the period for application submission to five years and six months if pediatric studies are completed within a specified timeframe. The Act \"Better Pharmaceuticals for Children Act\" extends market exclusivity for pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act, adjusting the period to three years and six months if pediatric studies are completed within a specified timeframe. The Act extends market exclusivity for pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act, adjusting the period to three years and six months if pediatric studies are completed within a specified timeframe. Additionally, for drugs subject to listed patents with certifications submitted under specific sections, the approval period may be extended by six months after patent expiration or if the patent is valid and infringed, approval may be delayed. The Secretary will develop a list of approved drugs for which additional pediatric information may be beneficial, in consultation with experts. Market exclusivity for already-marketed drugs may be extended if pediatric studies are requested by the Secretary. The Secretary may request pediatric studies for approved drugs, and if completed within a specified time frame, the market exclusivity period may be extended. The market exclusivity period for drugs may be extended by three years and six months under certain conditions related to pediatric studies and listed patents. The market exclusivity period for drugs can be extended by six months after patent expiration if the patent is valid and would be infringed in litigation. Additionally, the Secretary may request pediatric studies. The Secretary may request pediatric studies from drug sponsors or holders, and if agreed upon, written protocols for the studies must be completed and reports submitted to satisfy the studies requirement. The Secretary will review studies conducted according to written agreements and notify the sponsor. If protocols are not agreed upon, completion and acceptance of the studies by the Secretary will satisfy the requirement. The Secretary will review and accept or reject reports of pediatric studies within 90 days to ensure they meet scientific standards and filing requirements. If approval may occur after submission of these studies, market exclusivity may be delayed. The Secretary will delay acceptance or approval of drug submissions under section 505(b)(2) or 505(j) until determining if pediatric study requirements have been met, with a maximum delay of 90 days. Once requirements are satisfied, market exclusivity period will be considered to have been running during the delay. The Secretary will publish notice of determinations on study requirements for drug submissions under section 505(b)(2) or (j). The section defines pediatric studies as clinical investigations in pediatric age-groups for drugs. It also limits market exclusivity for new drugs and sets a sunset date for exclusivity based on studies commenced after January 1, 2004. The Secretary will report to Congress by January 1, 2003 on the program's experience. The study and report will assess the effectiveness of the pediatric drug program, the adequacy of incentives provided, the economic impact, and suggest any modifications deemed appropriate by the Secretary."
}